Foundayo GLP-1 Pill: FDA Needs More Data
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Foundayo GLP-1 Pill: FDA Needs More Data
-
Narrated by:
-
By:
Summary
Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use.
Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.
adbl_web_anon_alc_button_suppression_c
No reviews yet